We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us

Download Mobile App


15 Apr 2024 - 17 Apr 2024
23 Apr 2024 - 26 Apr 2024
25 Apr 2024 - 27 Apr 2024

Roche and Sysmex Expand 25-Year Partnership to Foster More Sustainable Diagnostic Solutions

By LabMedica International staff writers
Posted on 04 Aug 2023
Print article
Image: Roche will continue to offer Sysmex hematology products based on the renewed terms (Photo courtesy of Sysmex)
Image: Roche will continue to offer Sysmex hematology products based on the renewed terms (Photo courtesy of Sysmex)

Roche (Basel, Switzerland) and Sysmex Corporation (Kobe, Japan) have expanded their Global Business Partnership Agreement. The renewed agreement reinforces the commitment of both companies to their long-established collaboration. Under the revised terms, Roche, which has been collaborating with Sysmex for 25 years, will continue to offer Sysmex's hematology products, complementing its comprehensive laboratory solutions portfolio. The Global Business Partnership Agreement between Roche and Sysmex promises to assist patients requiring diagnostic solutions and aims to enhance the efficiency and effectiveness of lab testing by offering integrated in-vitro diagnostics (IVD) technologies through a single provider.

The commercial and R&D collaboration between Roche and Sysmex was initiated in 1998, and the companies have since consistently strengthened their partnership. In 2020, both companies signed the Global Business Partnership Agreement to broaden their partnership further and enhance the customer experience. As of 2023, with updated terms and an expanded scope, both companies have reaffirmed their long-standing partnership and commitment to fostering a more sustainable future for society. The revised non-exclusive agreement ushers in a new dimension of cooperation, incorporating an additional eco-social agreement to jointly investigate more sustainable diagnostic solutions. By extending their long-standing collaboration beyond the current portfolio, both companies have demonstrated their commitment to seeking more sustainable solutions.

“We are delighted to expand our 25-year partnership with Sysmex in the area of hematology and in exploring more sustainable diagnostics solutions,” said Matt Sause, CEO of Roche Diagnostics. “Roche and Sysmex both have a long-standing history of delivering reliable and innovative solutions for patients and I am very happy to see this collaboration grow.”

“We are pleased to announce the renewal of our partnership with Roche, reaffirming our commitment to long-term collaboration,” added Kaoru Asano, President of Sysmex Corporation. “Developing our partnerships in the field of diagnostics even further and addressing enduring eco-social challenges represents a significant milestone in advancing our alliance to the next level. Together, we firmly believe in making even greater contributions to our customers in laboratories and creating a sustainable society."

Related Links:
Sysmex Corporation

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
POCT Fluorescent Immunoassay Analyzer
Gold Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay

Print article


Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Molecular Diagnostics

view channel
Image: AI analysis of DNA fragmentomes and protein biomarkers noninvasively detects ovarian cancer (Photo courtesy of Adobe Stock)

Blood-Based Machine Learning Assay Noninvasively Detects Ovarian Cancer

Ovarian cancer is one of the most common causes of cancer deaths among women and has a five-year survival rate of around 50%. The disease is particularly lethal because it often doesn't cause symptoms... Read more


view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more


view channel
Image: The groundbreaking treatment approach has shown promise in hard-to-treat cancers (Photo courtesy of 123RF)

Genetic Testing Combined With Personalized Drug Screening On Tumor Samples to Revolutionize Cancer Treatment

Cancer treatment typically adheres to a standard of care—established, statistically validated regimens that are effective for the majority of patients. However, the disease’s inherent variability means... Read more


view channel
Image: ‘Virtual biopsy’ allows clinicians to analyze skin noninvasively (Photo courtesy of Stanford Medicine)

Virtual Skin Biopsy Determines Presence of Cancerous Cells

When dermatologists spot an unusual mark on a patient's skin, they face a choice: monitor it for some time or remove it for biopsy. Similarly, when removing breast tumors, surgeons must send excised tissues... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.